Please login to the form below
Troxyca ER
This page shows the latest Troxyca ER news and features for those working in and with pharma, biotech and healthcare.
FDA panel backs Pfizer and Teva abuse-resistant painkillers
In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result. ... The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- FDA approves Roche’s Actemra COVID-19 trial
- 3 ways to increase patient retention rates in clinical trials
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
Quick links
Infographics
